Traws Pharma, Inc.

TRAW

Held by 1 specialist biotech fund

Share on X

Fund Holdings

OrbiMed Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 605,531Value: $684K

**Signal Note: OrbiMed Entry into Traws Pharma** OrbiMed's $684K initiating position in TRAW signals conviction in the company's pipeline, likely centered on its lead asset TRW062 (a GABA-A modulator in development for cortisol-related disorders). The timing suggests tracking toward clinical milestones; investors should monitor for Phase 2 data readouts or partnership announcements that could validate the mechanism in stress-related indications.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

APLS1 fund RNA1 fund BIOA1 fund IRON1 fund ANRO1 fund FOLD1 fund BCAX1 fund ARGX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: